Matthew K. Wun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matthew K. Wun has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Richard Malik
Centre for Veterinary Education The University of Sydney Sydney New South Wales Australia
6 shared publications - Nicolas Francisco Villarino
Department of Veterinary Clinical Sciences, College of Veterinary Medicine Washington State University Pullman Washington USA
3 shared publications Sarah Davies
Veterinary Imaging Associates, 52-56 Atchison St, St Leonards, NSW 2065, Australia
3 shared publications- Jan Šlapeta
Sydney School of Veterinary Science, Faculty of Science, The University of Sydney, Sydney, NSW, Australia
2 shared publications Jane Yu
Sydney School of Veterinary Science, The University of Sydney, Camperdown, NSW 2006, Australia
2 shared publications- Michael H. Court
Department of Veterinary Clinical Sciences, College of Veterinary Medicine Washington State University Pullman Washington USA
2 shared publications
Latest Publications
- Open Access
- 8 March 2026
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 49 (2) , 228-230
Should Injectable Meloxicam Be Approved for Use in Cats?
Injectable meloxicam remains widely used in feline practice despite its association with acute kidney injury (AKI). Evidence of this association was apparent in the results of a clinical trial submitted to the U.S. Food and Drug Administration as part of a New Animal Drug Application (NADA) Freedom of Information Summary. These data, however, were omitted from the published version of that clinical trial in the Journal of the American Veterinary Medical Association (JAVMA). The study's financial sponsorship by the drug manufacturer raises ethical concerns, especially given meloxicam's ongoing and enthusiastic promotion by veterinary organizations also financially supported by the manufacturer. This viewpoint questions meloxicam's approval process and highlights the potential influence of pharmaceutical industry sponsorship on veterinary prescribing practices and policy.
- 8 March 2026
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 49 (2) , 228-230
Open AccessShould Injectable Meloxicam Be Approved for Use in Cats?
Injectable meloxicam remains widely used in feline practice despite its association with acute kidney injury (AKI). Evidence of this association was apparent in the results of a clinical trial submitted to the U.S. Food and Drug Administration as part of a New Animal Drug Application (NADA) Freedom of Information Summary. These data, however, were omitted from the published version of that clinical trial in the Journal of the American Veterinary Medical Association (JAVMA). The study's financial sponsorship by the drug manufacturer raises ethical concerns, especially given meloxicam's ongoing and enthusiastic promotion by veterinary organizations also financially supported by the manufacturer. This viewpoint questions meloxicam's approval process and highlights the potential influence of pharmaceutical industry sponsorship on veterinary prescribing practices and policy.
- 18 January 2026
- Published by Wiley in Journal of Veterinary Emergency and Critical Care
- Vol. 36 (1) , 39-44
Evaluation of Urinary Tissue Inhibitor of Metalloproteinase‐2 (TIMP‐2), Insulin‐Like Growth Factor–Binding Protein‐7 (IGFBP‐7), and Kidney Injury Molecule‐1 (KIM‐1) as Biomarkers for the Detection of Meloxicam‐Induced Kidney Injury in Cats
Objective: To evaluate the concentration versus time course profiles of urinary tissue inhibitor of metalloproteinase‐2 (TIMP‐2), insulin‐like growth factor–binding protein‐7 (IGFBP‐7), and kidney injury molecule‐1 (KIM‐1) during repeated administrations of meloxicam, and determine whether these profiles differ from saline‐treated cats. Design: Placebo‐controlled experimental design performed in 2017. Animals: Twelve healthy, adult, purpose‐bred female cats. Interventions: Cats were randomly allocated to control and treatment groups. Cats in the treatment group ( n = 6) received meloxicam 0.3 mg/kg subcutaneously every 24 h for 31 days. Cats in the control group ( n = 6) received saline (0.1 mL/kg subcutaneously). Measurements and Main Results: Urinary TIMP‐2, IGFBP‐7, KIM‐1, and creatinine were measured every 4–6 days for 31 days, along with serum creatinine. In the treatment group, cats were determined to have renal injury if at least one kidney had histopathological evidence of tubular damage, basement membrane damage, and/or interstitial inflammation. The urinary biomarker concentrations between control and renal injury groups were compared by calculating the area under the curve (AUC) for each biomarker normalized for urine creatinine (UC) concentration versus time course profile and reported as mean ± SE. The AUC values for the two groups were compared statistically using an unpaired, two‐tailed t ‐test. The AUC for urinary IGFBP‐7/UC was higher ( p = 0.0152) in the treatment group (0.042 ± 0.0062) compared to the control group (0.02676 ± 0.0018). The AUC for urinary KIM‐1/UC was higher ( p = 0.0083) in the treatment group (0.034 ± 0.0055) compared to the control group (0.019 ± 0.0022). An increase in urinary TIMP‐2 was detected in only 50% of the treatment group. Conclusions: Urinary IGFBP‐7 and KIM‐1 increase in cats that develop acute kidney injury after repeated meloxicam administration. Further studies are needed before the clinical utility of these molecules as biomarkers for early acute kidney injury detection in cats can be determined.
- 18 January 2026
- Published by Wiley in Journal of Veterinary Emergency and Critical Care
- Vol. 36 (1) , 39-44
Evaluation of Urinary Tissue Inhibitor of Metalloproteinase‐2 (TIMP‐2), Insulin‐Like Growth Factor–Binding Protein‐7 (IGFBP‐7), and Kidney Injury Molecule‐1 (KIM‐1) as Biomarkers for the Detection of Meloxicam‐Induced Kidney Injury in Cats
Objective: To evaluate the concentration versus time course profiles of urinary tissue inhibitor of metalloproteinase‐2 (TIMP‐2), insulin‐like growth factor–binding protein‐7 (IGFBP‐7), and kidney injury molecule‐1 (KIM‐1) during repeated administrations of meloxicam, and determine whether these profiles differ from saline‐treated cats. Design: Placebo‐controlled experimental design performed in 2017. Animals: Twelve healthy, adult, purpose‐bred female cats. Interventions: Cats were randomly allocated to control and treatment groups. Cats in the treatment group ( n = 6) received meloxicam 0.3 mg/kg subcutaneously every 24 h for 31 days. Cats in the control group ( n = 6) received saline (0.1 mL/kg subcutaneously). Measurements and Main Results: Urinary TIMP‐2, IGFBP‐7, KIM‐1, and creatinine were measured every 4–6 days for 31 days, along with serum creatinine. In the treatment group, cats were determined to have renal injury if at least one kidney had histopathological evidence of tubular damage, basement membrane damage, and/or interstitial inflammation. The urinary biomarker concentrations between control and renal injury groups were compared by calculating the area under the curve (AUC) for each biomarker normalized for urine creatinine (UC) concentration versus time course profile and reported as mean ± SE. The AUC values for the two groups were compared statistically using an unpaired, two‐tailed t ‐test. The AUC for urinary IGFBP‐7/UC was higher ( p = 0.0152) in the treatment group (0.042 ± 0.0062) compared to the control group (0.02676 ± 0.0018). The AUC for urinary KIM‐1/UC was higher ( p = 0.0083) in the treatment group (0.034 ± 0.0055) compared to the control group (0.019 ± 0.0022). An increase in urinary TIMP‐2 was detected in only 50% of the treatment group. Conclusions: Urinary IGFBP‐7 and KIM‐1 increase in cats that develop acute kidney injury after repeated meloxicam administration. Further studies are needed before the clinical utility of these molecules as biomarkers for early acute kidney injury detection in cats can be determined.
- Open Access
- 11 October 2025
- Published by Wiley in Veterinary Clinical Pathology
- Vol. 54 (4) , 362-368
Recognition of Transfusion With Microcytic Packed Red Blood Cells on ADVIA 2120i RBC V/ HC Cytograms: A Case Report
A 3‐year‐old, intact female Havanese dog was presented for treatment of a relapse of suspected immune‐mediated anemia and thrombocytopenia. Over the course of treatment, the patient's anemia appeared to acutely transition from macrocytic and hypochromic to microcytic and hypochromic between days five and six of hospitalization. Assessment of red blood cell volume/hemoglobin content (RBC V/HC) cytograms produced on the ADVIA 2120i (Siemens Healthcare Diagnostics, Munich, Germany) revealed a new population of microcytic and hypochromic erythrocytes on day six of hospitalization. This finding prompted the consideration that the microcytic and hypochromic erythrocyte population was introduced to the patient via a packed red blood cell (pRBC) transfusion, which was confirmed after running a sample of pRBCs from the same donor through the ADVIA 2120i. Other causes of microcytosis, such as iron deficiency anemia, portosystemic shunt, and hyponatremia, were additionally investigated and considered less likely. The cause of the microcytosis in the donor was ultimately undetermined. To the authors' knowledge, this is the first case where inadvertent transfusion with microcytic pRBCs was discovered with the aid of RBC V/HC cytograms. This case highlights the importance of considering pRBCs as a source of changes in erythrocyte indices as well as the utility of RBC V/HC cytograms in patients with multiple populations of erythrocytes, such as those receiving transfusions. Additionally, this case prompts reconsideration of the need for standardization of guidelines for blood donation frequency and monitoring of iron status in frequent blood donors.
- 11 October 2025
- Published by Wiley in Veterinary Clinical Pathology
- Vol. 54 (4) , 362-368
Open AccessRecognition of Transfusion With Microcytic Packed Red Blood Cells on ADVIA 2120i RBC V/ HC Cytograms: A Case Report
A 3‐year‐old, intact female Havanese dog was presented for treatment of a relapse of suspected immune‐mediated anemia and thrombocytopenia. Over the course of treatment, the patient's anemia appeared to acutely transition from macrocytic and hypochromic to microcytic and hypochromic between days five and six of hospitalization. Assessment of red blood cell volume/hemoglobin content (RBC V/HC) cytograms produced on the ADVIA 2120i (Siemens Healthcare Diagnostics, Munich, Germany) revealed a new population of microcytic and hypochromic erythrocytes on day six of hospitalization. This finding prompted the consideration that the microcytic and hypochromic erythrocyte population was introduced to the patient via a packed red blood cell (pRBC) transfusion, which was confirmed after running a sample of pRBCs from the same donor through the ADVIA 2120i. Other causes of microcytosis, such as iron deficiency anemia, portosystemic shunt, and hyponatremia, were additionally investigated and considered less likely. The cause of the microcytosis in the donor was ultimately undetermined. To the authors' knowledge, this is the first case where inadvertent transfusion with microcytic pRBCs was discovered with the aid of RBC V/HC cytograms. This case highlights the importance of considering pRBCs as a source of changes in erythrocyte indices as well as the utility of RBC V/HC cytograms in patients with multiple populations of erythrocytes, such as those receiving transfusions. Additionally, this case prompts reconsideration of the need for standardization of guidelines for blood donation frequency and monitoring of iron status in frequent blood donors.
- Open Access
- 23 September 2025
- Published by Elsevier in Veterinary Anaesthesia and Analgesia
- Vol. 52 (6) , 730-736
The association between injectable non-steroidal anti-inflammatory drugs and acute kidney injury in dogs and cats
- 23 September 2025
- Published by Elsevier in Veterinary Anaesthesia and Analgesia
- Vol. 52 (6) , 730-736
Open AccessThe association between injectable non-steroidal anti-inflammatory drugs and acute kidney injury in dogs and cats
- Open Access
- 1 May 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (3) , e70075
Letter Regarding “Comparison of 2 Assays for Measuring Serum Total Thyroxine Concentration in Dogs and Cats”
- 1 May 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (3) , e70075
Open AccessLetter Regarding “Comparison of 2 Assays for Measuring Serum Total Thyroxine Concentration in Dogs and Cats”
- Open Access
- 1 March 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (2) , e70033
Response to Response to Letter Regarding “An Artificial Neural Network-Based Model to Predict Chronic Kidney Disease in Aged Cats”
- 1 March 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (2) , e70033
Open AccessResponse to Response to Letter Regarding “An Artificial Neural Network-Based Model to Predict Chronic Kidney Disease in Aged Cats”
- Open Access
- 1 March 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (2) , e70019
Response to Response to Letter Regarding “Plasma Concentration of Thrombopoietin in Dogs With Immune Thrombocytopenia”
- 1 March 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (2) , e70019
Open AccessResponse to Response to Letter Regarding “Plasma Concentration of Thrombopoietin in Dogs With Immune Thrombocytopenia”
- Open Access
- 1 March 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (2) , e70001
Letter Regarding “An Artificial Neural Network-Based Model to Predict Chronic Kidney Disease in Aged Cats”
- 1 March 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (2) , e70001
Open AccessLetter Regarding “An Artificial Neural Network-Based Model to Predict Chronic Kidney Disease in Aged Cats”
- Open Access
- 1 January 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (1) , e17244
Letter regarding “Plasma concentration of thrombopoietin in dogs with immune thrombocytopenia”
- 1 January 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (1) , e17244
Open AccessLetter regarding “Plasma concentration of thrombopoietin in dogs with immune thrombocytopenia”
- Open Access
- 1 January 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (1) , e17260
Letter regarding “Peripheral and intestinal T lymphocyte subsets in dogs with chronic inflammatory enteropathy”
- 1 January 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (1) , e17260
Open AccessLetter regarding “Peripheral and intestinal T lymphocyte subsets in dogs with chronic inflammatory enteropathy”